Envestnet Asset Management Inc. Has $1.68 Million Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Envestnet Asset Management Inc. reduced its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 18.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,845 shares of the biotechnology company’s stock after selling 9,382 shares during the period. Envestnet Asset Management Inc.’s holdings in Viking Therapeutics were worth $1,684,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of VKTX. Blue Trust Inc. increased its stake in Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 309 shares in the last quarter. YANKCOM Partnership bought a new stake in Viking Therapeutics in the fourth quarter valued at approximately $33,000. CIBC Private Wealth Group LLC increased its stake in Viking Therapeutics by 170.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 851 shares in the last quarter. S.A. Mason LLC increased its stake in Viking Therapeutics by 20.0% in the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 300 shares in the last quarter. Finally, Wolff Wiese Magana LLC bought a new stake in Viking Therapeutics in the fourth quarter valued at approximately $75,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Trading Up 3.8 %

Viking Therapeutics stock opened at $25.94 on Tuesday. The company has a market cap of $2.91 billion, a P/E ratio of -25.94 and a beta of 0.84. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $81.86. The company has a fifty day simple moving average of $26.35 and a 200 day simple moving average of $40.06.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.26) EPS. On average, equities research analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Truist Financial reaffirmed a “buy” rating and issued a $75.00 target price (down previously from $95.00) on shares of Viking Therapeutics in a research note on Monday. Raymond James increased their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 6th. Cantor Fitzgerald initiated coverage on shares of Viking Therapeutics in a research report on Monday. They set an “overweight” rating and a $104.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday, April 24th. Finally, Piper Sandler lowered their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating for the company in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $87.15.

Insider Buying and Selling at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan purchased 1,240 shares of the business’s stock in a transaction on Monday, March 31st. The stock was purchased at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the purchase, the director now directly owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.